• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, September 7, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Solving the thermoelectric ‘trade-off’ conundrum with metallic carbon nanotubes

Bioengineer by Bioengineer
December 2, 2019
in Science News
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Strategy to bypass trade-off between thermoelectric voltage and conductivity

IMAGE

Credit: Tokyo Metropolitan University


Tokyo, Japan – Scientists from Tokyo Metropolitan University have used aligned “metallic” carbon nanotubes to create a device which converts heat to electrical energy (a thermoelectric device) with a higher power output than pure semiconducting carbon nanotubes (CNTs) in random networks. The new device bypasses the troublesome trade-off in semiconductors between conductivity and electrical voltage, significantly outperforming its counterpart. High power thermoelectric devices may pave the way for more efficient use of waste heat, like wearable electronics.

Thermoelectric devices can directly convert heat to electricity. When we think about the amount of wasted heat in our environment like in air conditioning exhausts, vehicle engines or even body heat, it would be revolutionary if we could somehow scavenge this energy back from our surroundings and put it to good use. This goes some way to powering the thought behind wearable electronics and photonics, devices which could be worn on the skin and powered by body heat. Limited applications are already available in the form of body heat powered lights and smartwatches.

The power extracted from a thermoelectric device when a temperature gradient is formed is affected by the conductivity of the device and the Seebeck coefficient, a number indicating how much electrical voltage is generated with a certain difference in temperature. The problem is that there is a trade-off between the Seebeck coefficient and conductivity: the Seebeck coefficient drops when the device is made more conductive. To generate more power, we ideally want to improve both.

Semiconducting materials are generally considered superior candidates for high-performance thermoelectric devices. However, a team led by Prof. Kazuhiro Yanagi of Tokyo Metropolitan University met an unlikely hero in the form of “metallic” CNTs. Unlike purely semiconducting CNTs, they found that they could simultaneously enhance both the conductivity and Seebeck coefficient of metallic CNTs, breaking the trade-off between these two key quantities. The team went on to show that these unique characteristics arose from the one-dimensional metallic electronic structure of the material. Furthermore, they were able to align the orientation of the metallic CNTs, achieving an output which was nearly five times that of films of randomly oriented pure semiconducting CNTs.

Not only will high-performance thermoelectric elements let us use body heat to power our smartphones, the potential biomedical applications will ensure that they play an important role in everyday applications in the future.

###

This work was supported by the JSPS KAKENHI Program through Grant Numbers JP17H06124, JP17H01069, and JP18H01816, and the JST CREST Program through Grant Number JPMJCR17I5.

Media Contact
Go Totsukawa
[email protected]
81-426-772-728

Original Source

https://pubs.acs.org/doi/10.1021/acs.nanolett.9b03022

Related Journal Article

http://dx.doi.org/10.1021/acs.nanolett.9b03022

Tags: Chemistry/Physics/Materials SciencesElectrical Engineering/ElectronicsIndustrial Engineering/ChemistryMaterialsNanotechnology/MicromachinesSuperconductors/SemiconductorsTechnology/Engineering/Computer Science
Share12Tweet8Share2ShareShareShare2

Related Posts

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

September 7, 2025

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

September 7, 2025

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

September 7, 2025

Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment

September 7, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    55 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations

Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC

FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.